Search research articles
Contact Us
Filters
Showing results (151-160 of 164) with videos related to
Page
of 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 29, 2025
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab Plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Jérôme Fayette, Lisa Licitra, Kevin Harrington, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 15, 2024
Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study
Erika Hamilton, Matthew D Galsky, Sebastian Ochsenreither, et al.
Cancer Treatment Reviews
|
June 28, 2026
Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck
Carlo Resteghini, Athanassios Argiris, Pierre Blanchard, et al.
The Lancet. Oncology
|
April 1, 2024
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
Jean-Pascal Machiels, Yungan Tao, Lisa Licitra, et al.
Urologic Oncology
|
June 20, 2015
Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features
Romain Mathieu, Géraldine Pignot, Alexandre Ingles, et al.
Nature Communications
|
January 31, 2025
PPARα-mediated lipid metabolism reprogramming supports anti-EGFR therapy resistance in head and neck squamous cell carcinoma
Valentin Van den Bossche, Julie Vignau, Engy Vigneron, et al.
Journal for Immunotherapy of Cancer
|
May 16, 2022
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade
Carlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2024
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
Tanya Dorff, Lisa G Horvath, Karen Autio, et al.
The Lancet. Oncology
|
January 12, 2013
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
Gwenaelle Gravis, Karim Fizazi, Florence Joly, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 15, 2024
The european organisation for research and treatment of cancer head and neck cancer module (EORTC QLQ-HN43): Estimates for minimal important difference and minimal important change
Susanne Singer, Eva Hammerlid, Iwona M Tomaszewska, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 164) with videos related to
Sort By:
Page
of 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 29, 2025
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab Plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Jérôme Fayette, Lisa Licitra, Kevin Harrington, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 15, 2024
Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study
Erika Hamilton, Matthew D Galsky, Sebastian Ochsenreither, et al.
Cancer Treatment Reviews
|
June 28, 2026
Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck
Carlo Resteghini, Athanassios Argiris, Pierre Blanchard, et al.
The Lancet. Oncology
|
April 1, 2024
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
Jean-Pascal Machiels, Yungan Tao, Lisa Licitra, et al.
Urologic Oncology
|
June 20, 2015
Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features
Romain Mathieu, Géraldine Pignot, Alexandre Ingles, et al.
Nature Communications
|
January 31, 2025
PPARα-mediated lipid metabolism reprogramming supports anti-EGFR therapy resistance in head and neck squamous cell carcinoma
Valentin Van den Bossche, Julie Vignau, Engy Vigneron, et al.
Journal for Immunotherapy of Cancer
|
May 16, 2022
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade
Carlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2024
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
Tanya Dorff, Lisa G Horvath, Karen Autio, et al.
The Lancet. Oncology
|
January 12, 2013
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
Gwenaelle Gravis, Karim Fizazi, Florence Joly, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 15, 2024
The european organisation for research and treatment of cancer head and neck cancer module (EORTC QLQ-HN43): Estimates for minimal important difference and minimal important change
Susanne Singer, Eva Hammerlid, Iwona M Tomaszewska, et al.
Page
of 17